Clinical Research Directory
Browse clinical research sites, groups, and studies.
Botulinum Toxin in Raynaud's Phenomenon
Sponsor: Emory University
Summary
Raynaud's Phenomenon (RP) is the most common vasospastic disorder encountered by hand surgeons with an estimated prevalence of 5% in the general population. It's manifestations are broad, and can range from minor to severe. Sometimes it can be refractory to treatments. The goal of this study is to evaluate the efficacy of Botulinum toxin (BT) in the treatment of treatment refractory RP by objective and subjective measures.
Official title: Double Blind RCT to Evaluate the Effect of Botulinum Toxin in Raynaud Phenomenon
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2022-02-10
Completion Date
2025-12
Last Updated
2025-02-12
Healthy Volunteers
No
Conditions
Interventions
Botulinum toxin
Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium botulinum that prevents the release of the neurotransmitter acetylcholine from the neuromuscular junction, thereby preventing muscular contraction. Eligible subjects will be randomized 1:1:1 into three different groups: 1) placebo 2) 10 Units of BT injected per digit and 3) 20 units of BT injected per digit.
Locations (1)
Emory University Hospital
Atlanta, Georgia, United States